0
Clinical Oncologist
Dr Tan Ai Lian
MD (China Medical University, Taiwan), FRCR (Clinical Oncology, UK)
Area of Focus
- Lung Cancer
- Head and Neck Cancer
- GI and Hepatobiliary Tract Cancer
- Breast Cancer
Locations
- Curie Penang (Bagan Specialist Centre)
Dr Tan Ai Lian is a Clinical Oncologist at Curie Penang (Bagan Specialist Centre). She is a Fellow of the Royal College of Radiologists in Clinical Oncology (UK), admitted in 2015, and holds her Doctor of Medicine from China Medical University, Taiwan.
Dr Tan has extensive experience in clinical oncology across Malaysia, having served as Clinical Oncologist at Hospital Pulau Pinang and Hospital Sultan Ismail, Johor Bahru, alongside visiting oncologist duties at Hospital Alor Setar. She undertook further training in oncology at Preston Hospital in the United Kingdom, and at the National Cancer Centre Singapore.
She has been Principal Investigator on more than 20 international, industry-sponsored clinical trials spanning lung, head and neck, gastrointestinal, hepatobiliary and breast cancers, reflecting her active involvement in advancing cancer treatment and research. Dr Tan is fluent in Bahasa Malaysia, English, Mandarin, Hokkien and Cantonese, enabling her to care for a broad range of patients.
- Asian Pacific Journal of Cancer Prevention, Vol 13, 2012: Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Penang General Hospital Experience
- Asian Pacific Journal of Cancer Prevention, Vol 13, 2012: Superiority of target volume coverage with intensity-modulated radiotherapy compared to 3D conformal radiotherapy in nasopharyngeal carcinoma: Penang General Hospital Experience.
- Medical Journal Malaysia Vol 69 No 3 2014: Chemotherapy Extravasation at Hospital Pulau Pinang, Malaysia
- 1st line Gefitinib in EGFR +ve metastatic adenocarcinoma patient: A retrospective cohort study in Hospital Pulau Pinang
| No. | Tumor Type | Study Title |
|---|---|---|
| 1 | Lung Cancer | ASCEND-8, A Randomized Phase 1 Study of Ceritinib, 450mg or 600mg, taken with Low-Fat Meal vs 750mg in Fasted State on Patient with ALK Rearranged Metastatic NSCLC |
| 2 | Lung Cancer | EMPOWER-Lung 1 (Multicenter, Randomized, Phase III Clinical Trial of Cemiplimab monotherapy of 1st line Treatment of advanced NSCLC with PD-L1 > 50%) in Hospital Pulau Pinang |
| 3 | Lung Cancer | EMPOWER-Lung 2 (Phase 3 study on efficacy and safety of combination of cemiplimab, ipilimumab and platinum-based double chemotherapy vs pembrolizumab monotherapy in 1st line treatment of advanced NSCLC) |
| 4 | Lung Cancer | CANOPY-A Study (Multicenter, Randomized, Phase 3 Clinical Trial of Adjuvant Canakinumab in Resected Non-Small Cell Lung Cancer) in Hospital Pulau Pinang |
| 5 | Lung Cancer | LAURA trial (Osimertinib Maintenance in Stage III EGFR mutant after definitive CCRT) in Hospital Pulau Pinang |
| 6 | Lung Cancer | ADAURA II Trial (Adjuvant Osimertinib vs placebo in completely Resected Stage IA2-IA3 EGFR mutated NSCLC) in Hospital Pulau Pinang |
| 7 | Lung Cancer | KEYVIBE Study (open-label Phase 3 Study MK-7684A (coformulation of Vibostolimab with Pembrolizumab) in Combination with CCRT followed by MK-7684A vs CCRT followed by Durvalumab in Participants with Unresectable, Locally Advanced Stage III NSCLC) |
| 8 | Lung Cancer | R3767-ONC-2266 (Phase 2 Perioperative Trial of Fianlimab and Cemiplimab, in combination with Chemotherapy vs Cemiplimab in combination with chemotherapy in patients with resectable Early Stage NSCLC) |
| 9 | Lung Cancer | R3767-ONCO-2235 (Randomized, double-blind Phase 2/3 Study of Fianlimab (Anti-LAG3 Ab) in combination with Cemiplimab vs Cemiplimab monotherapy in 1st line Treatment in patients with Advanced NSCLC with PD-L1 > 50%) |
| 10 | Lung Cancer | R3767-ONO-2236 (Randomized, double-blind Phase 2/3 Study of Fianlimab and Cemiplimab in combination with chemotherapy vs Cemiplimab in combination with chemotherapy irrespective of PD-L1 expression level) |
| 11 | Lung Cancer | SAFFRON Study (A Phase III, Randomised, Open-Label Study of Savolitinib in Combination with Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants with EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib) |
| 12 | Lung Cancer | Amlmerge Study (A Phase 2, Open-Label, Single-Arm Study of Amivantamab and Lazertinib Combination Therapy as 1st line Treatment in Patients with EGFR Mutated Recurrent Non-Small Cell Lung Cancer after Previous Treatment with Adjuvant Osimertinib in Early Stage Lung Cancer) |
| 13 | Lung Cancer | ARTEMIDE-Lung02 (A Phase III, Randomized, Double-Blind, Multicentre Global Study of Rilvegostomig or Pembrolizumab in combination with platinum chemotherapy as 1st line Treatment of patients with metastatic SCC Non-Small Cell Lung Cancer who express PD-L1) |
| 14 | Lung Cancer | V940-002 Trial (INTerpath-002) (A phase 3, Randomized, Double-Blind, Placebo and/or Active Comparator Controlled Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab vs Adjuvant Placebo + Pembrolizumab in Patients with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer) |
| 15 | Lung Cancer | TROPION-Lung12 (A Phase III, Randomised, Open-Label, Global Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy vs Standard of Care, Following Complete Tumour Resection, in Participants With Stage 1 Adenocarcinoma Non-Small Cell Cancer who are ctDNA+ or have High Risk Pathologic Features) |
| 16 | Lung Cancer | DAREON-Lung 1 (Phase III, Randomised, Double-Blinded Study in Extensive Stage Small Cell Lung Cancer to Compare Obrixtamig + Atezolizumab + Etoposide + Carboplatin vs Placebo + Atezolizumab + Etoposide + Carboplatin) |
| 17 | Head and Neck Cancer | FF01 Trial (Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine and Carboplatin vs Gemcitabine and Carboplatin as first line Treatment for Advanced Nasopharyngeal Carcinoma Patients) |
| 18 | Head and Neck Cancer | eVOLVE-HNSCC (Phase 3, Randomized, Multicentre, Global Study of Volrustomig (MEDI5752) as Sequential Therapy vs Observation in Participants with Unresected Locally Advanced Head and Neck SCC, who have not progressed following Definitive CCRT) |
| 19 | Head and Neck Cancer | BCA101 (Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa or Placebo in Combination With Pembrolizumab for 1st line Treatment of PD-L1 +ve, Recurrent or Metastatic Head and Neck SCC) |
| 20 | GI + Hepatobiliary Tract Cancer | KEYNOTE-966 (Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin vs Placebo Plus Gemcitabine/Cisplatin as First Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma) in Hospital Pulau Pinang |
| 21 | GI + Hepatobiliary Tract Cancer | EMERALD-3 (Phase 3, Randomized, Open-Label, Multicentre Study of Durvalumab in combination with Tremelimumab ± Lenvatinib Given concurrently with TACE compared to TACE alone in patients with Locoregional Hepatocellular Carcinoma) |
| 22 | GI + Hepatobiliary Tract Cancer | A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (Stomach and pancreas) |
| 23 | GI + Hepatobiliary Tract Cancer | DESTINY-BTC01 (Phase 3 of T-DXd and Rilvegostomig vs Standard of Care Gemcitabine, Cisplatin, and Durvalumab for 1st line Locally Advanced or Metastatic HER2-Expressing Biliary Tract Cancer) |
| 24 | GI + Hepatobiliary Tract Cancer | TroFuse-015 Study (Phase 3, Multicenter, Open-Label, Randomized Study to Compare the Efficacy and Safety of MK-2870 vs Treatment of Physician’s Choice in 3L+ Advanced/Metastatic GE Adenocarcinoma) |
| 25 | Breast Cancer | KEYNOTE-B49 (Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab + Chemotherapy in patients with HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer) |
Get in Touch With Our Specialists
Our team provides expert, personalized care for you or your loved ones.
